Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wayfair Inc (W) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wayfair Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Wayfair Inc trades at $89.4 (market cap $11.78B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.4× Wayfair Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | W | |
|---|---|---|
Market Cap | $39.89B | $11.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $119.05 |
52-Week Low | $278.09 | $53.37 |
Enterprise Value | $38.15B | $14.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Wayfair (W) trades at $89.23, down 1.18% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $92.64. The company shows revenue growth to $12.46 billion in 2025 but remains unprofitable with a net loss of $313 million. Recent earnings beat expectations in Q3 and Q4 2025, while Q1 2026 matched estimates. Wayfair is expanding into brick-and-mortar stores and leveraging AI, as highlighted in recent Bloomberg coverage.
The stock presents a mixed outlook: analyst sentiment is positive with 52% buy ratings, but profitability challenges and high debt-to-asset ratio of 95% pose risks. Near-term catalysts include Q2 2026 earnings on August 4, 2026, and store expansion initiatives. Investors should weigh growth potential against persistent losses and competitive pressures in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
